Oxidative damage in chemical teratogenesis

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 396, Issue 1-2, 1997, Pages 65-78

  Wells, Peter G ^a,b   Kim, Perry M ^a   Laposa, Rebecca R ^a   Nicol, Christopher J ^b   Parmana, Toufan ^a   Winn, Louise M ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Benzo a pyrene; Free radical; NNK; Oxidative stress; Phenytoin; Reactive intermediates; Reactive oxygen species; Teratogenesis; Thalidomide

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; ALPHA TOCOPHEROL; BENZO[A]PYRENE; CATALASE; CYCLOPHOSPHAMIDE; DEOXYRIBONUCLEOPROTEIN; DIAMIDE; DIMETHADIONE; DOXORUBICIN; ERGOTAMINE; FREE RADICAL; GLUTATHIONE; GLUTATHIONE REDUCTASE; HYDROXYUREA; MEPHENYTOIN; NICARDIPINE; NIFEDIPINE; NORMEPHENYTOIN; PHENYTOIN; PROSTAGLANDIN SYNTHASE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TERATOGENIC AGENT; THALIDOMIDE; TRIMETHADIONE; XENOBIOTIC AGENT;

CHEMICAL TERATOGENESIS; DNA DAMAGE; DNA REPAIR; EMBRYOTOXICITY; GENE MUTATION; GENOTOXICITY; HUMAN; IRRADIATION; LIPID PEROXIDATION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RABBIT; RAT; RESEARCH; REVIEW; SIGNAL TRANSDUCTION; TOXICOKINETICS; XENOBIOTIC METABOLISM;

EID: 0031565928     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(97)00175-9     Document Type: Article

References (57)

1. Juchau M.R., Lee Q.P., Fantel A.G. Xenobiotics biotransformation/bioactivation in organogenesis-stage conceptal tissues: Implications for embryotoxicity and teratogenesis. Drug Metab. Rev. 24:1992;195-238.
2. Winn L.M., Wells P.G. Free radical-mediated mechanisms of anticonvulsant teratogenicity. Eur. J. Neurol. 2(Suppl. 4):1995;5-29.
3. Fantel A.G. Reactive oxygen species in development toxicity: Review and hypothesis. Teratology. 53:1996;196-217.
4. Wells P.G., Winn L.M. Biochemical toxicology of chemical teratogenesis. Crit. Rev. Biochem. Mol. Biol. 31:1996;1-40.
5. P.G. Wells, L.M. Winn, The role of biotransformation in development toxicity, in: I.G. Sipes, C.A. McQueen, A.J. Gandolfi (Eds.), Comprehensive Toxicology, vol. 10: Reproductive and Endocrine Toxicology, Elsevier, Amsterdam, 1997, pp. 489-507.
6. Wells P.G., Obilo F.C., de Morais S.M.F. Benzo[a]pyrene embryopathy in rats genetically deficient in bilirubin UDP-glucuronyl transferase. FASEB J. 3:1989;A1025.
7. Kim P.M., Wells P.G. Phenytoin-initiated hydroxyl radical formation: Characterisation by enhanced salicylate hydroxylation. Mol. Pharmacol. 49:1996;172-181.
8. Kim P.M., Wells P.G. Genoprotection by UDP-glucuronosyltransferases in peroxidase-dependent, reactive oxygen species-mediated micronucleus initiation by the carcinogens 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and benzo[a]pyrene. Cancer Res. 56:1996;1526-1532.
9. Kim P.M., Winn L.M., Parman T., Wells P.G. UDP-glucuronosyltransferase-mediated protection against in vitro DNA oxidation, micronucleus formation and embryotoxicity initiated by phenytoin and its major metabolite 5-(p-hydroxyphenyl)-5-phenylhandantoin (HPPH). J. Pharmacol. Exp. Ther. 280:1997;200-209.
10. P.G. Wells, P.M. Kim, C.J. Nicol, T. Parman, L.M. Winn, Reactive intermediates, in: R.J. Kavlock, G.P. Daston (Eds.), Handbook of Experimental Pharmacology Drug Toxicity in Embryonic Development, Springer-Verlag, Berlin, 1996, pp. 451-516.
11. Parman T., Chen G., Bray T.M., Wells P.G. Bioactivation of phenytoin, thalidomide and related teratogens to a free radical intermediate using prostaglandin H synthase (PHS) or hepatic microsomes: Characterisation by electron spin resonance (ESR) spectrometry. Fundam. Appl. Toxicol. 30(suppl. 1 (2)):1996;246.
12. Winn L.M., Wells P.G. Phenytoin-initiated DNA oxidation in murine embryo culture, and embryoprotection by the antioxidative enzymes superoxide dismutase and catalase: Evidence for reactive oxygen species mediated DNA oxidation in the molecular mechanism of phenytoin teratogenicity. Mol. Pharmacol. 48:1995;112-120.
13. Juchau M.R., Fantel A.G., Harris C., Beyer B.K. The potential role of redox cycling as a mechanism for chemical teratogenesis. Environ. Health Perspect. 70:1986;131-136.
14. Kappus H. Overview of enzyme systems involved in bio-reduction of drugs and in redox cycling. Biochem. Pharmacol. 35:1986;1-6.
15. Fantel A.G., Barber C.V., Carda M.B., Tumbic R.W., Mackler B. Studies of the role of ischemic/reperfusion and superoxide anion radical production in the teratogenicity of cocaine. Teratology. 26:1992;293-300.
16. Danielsson B.R., Danielson K., Tomson T. Phenytoin causes phalangeal hypoplasia in the rabbit fetus at clinically relevant free plasma concentrations. Teratology. 52:1995;252-259.
17. Webster W.S., Brownwoodman P.D.C., Snow M.D., Danielsson B.R.G. Teratogenic potential of almokalant, dofetilide, and D-sotalol: Drugs with potassium channel blocking activity. Teratology. 53:1996;168-175.
18. DeSesso J.M., Scialli A.R., Goeringer G.C. D-Mannitol, a specific hydroxyl free radical scavenger, reduces the developmental toxicity of hydroxyurea in rabbits. Teratology. 49:1994;248-259.
19. Parman T., Mahendra A.S., Wiley M.J., Wells P.G. Inhibition of thalidomide-initiated DNA oxidation and teratogenicity in rabbits by the free radical spin trapping agent α-phenyl-N-t-butylnitrone (PBN). Fundam. Appl. Toxicol. 36(suppl. 1 (2)):1997;303.
20. Ozolins T.R.S., Siksay D.L.A., Wells P.G. Modulation of embryonic glutathione peroxidase activity and phenytoin teratogenicity by dietary deprivation of selenium in CD-1 mice. J. Pharmacol. Exp. Ther. 277:1996;945-953.
21. Winn L.M., Wells P.G. Evidence for embryonic prostaglandin H synthase-catalysed bioactivation and reactive oxygen species-mediated oxidation of macromolecules in phenytoin and benzo[a]pyrene teratogenesis. Free Rad. Biol. Med. 22:1997;607-621.
22. Nicol C.J., Wells P.G. Glucose-6-phosphate dehydrogenase: an embryoprotective enzyme in phenytoin teratogenesis. Fundam. Appl. Toxicol. 30(suppl. 1 (2)):1996;197.
23. Nicol C.J., Wells P.G. Glucose-6-phospahte dehydrogenase (G6PD) deficiency enhances phenytoin-initiated embryonic DNA oxidation and teratogenicity. Fundam. Appl. Toxicol. 36(suppl. 1 (2)):1997;98.
24. Hiranruengchok R., Harris C. Formation of protein-glutathione mixed disulfides in the developing rat conceptus following diamide treatment in vitro. Teratology. 52:1995;196-204.
25. Hiranruengchok R., Harris C. Diamide-induced alterations of intracellular thiol status and the regulation of glucose metabolism in the developing rat conceptus in vitro. Teratology. 52:1995;205-214.
26. Liu L., Wells P.G. DNA oxidation as a potential molecular mechanism mediating drug-induced birth defects: Phenytoin and structurally related teratogens initiate the formation of 8-hydroxy-2′-deoxyguanosine in vitro and in vivo in murine maternal hepatic and embryonic tissues. Free Rad. Biol. Med. 19:1995;639-648.
27. P.M. Kim, U. DeBoni, P.G. Wells, Peroxidase-dependent bioactivation and oxidation of DNA and protein in benzo[a]pyrene-initiated micronucleus formation, Free Rad. Biol. Med. (1997) in press.
28. Nicol C.J., Harrison M.L., Laposa R.R., Gimelshtein I.L., Wells P.G. A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nature Genet. 10:1995;181-187.
29. Laposa R.R., Wells P.G. Preliminary evaluation of phenytoin teratogenicity in transgenic mice deficient in the p53 tumor suppressor gene. Toxicologist. 15:1995;161.
30. Laposa R.R., Chan K.C., Wiley M.J., Wells P.G. Enhanced phenytoin embryopathy in p53-deficient mice: Characterisation of embryonic p53 genotype and the p53, p21 and Bax DNA damage response proteins. Fundam. Appl. Toxicol. 30(suppl. 1 (2)):1996;195.
31. Pacifici R.E., Davies K.J.A. Proteins, lipids and DNA repair systems in oxidative stress: The free-radical theory of aging revisited. Gerontology. 37:1991;166-180.
32. Stadtman E.R. Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Ann. Rev. Biochem. 62:1993;797-821.
33. Davies K.J.A., Gilbert B.C., Haywood R.M. Radical-induced damage to proteins: ESR spin-trapping studies. Free Radiat. Res. Commun. 15:1991;111-127.
34. Levine R.L., Garland D., Oliver C.N., Amici A., Climent I., Lenz A., Ahn B., Shaltiel S., Stadtman E.R. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol. 186:1990;464-478.
35. Liu L., Wells P.G. In vivo phenytoin-initiated oxidative damage to proteins and lipids in murine maternal hepatic and embryonic tissue organelles: Potential molecular targets mediating chemical teratogenesis. Toxicol. Appl. Pharmacol. 125:1994;247-255.
36. Liu L., Wells P.G. Potential molecular targets mediating chemical teratogenesis: In vitro peroxidase-catalysed phenytoin bioactivation and oxidative damage to proteins and lipids in murine maternal and embryonic tissues. Toxicol. Appl. Pharmacol. 134:1995;71-80.
37. H. Sies (Ed.), Oxidative Stress, Academic Press, New York, 1985.
38. B. Halliwell and J.M.C. Gutteridge (Eds.), Free Radicals in Biology and Medicine, 2nd ed. Clarendon, Oxford, 1989.
39. C. Harris, Hypoxia and altered redox status in embryotoxicity, in: R.J. Kavlock, G.P. Daston (Eds.), Handbook of Experimental Pharmacology, vol. 124, Part 1: Drug Toxicity in Embryonic Development, Springer-Verlag, Berlin, 1997, pp. 519-548.
40. Powis G., Briehl M., Oblong J. Redox signalling and the control of cell growth and death. Pharmac. Ther. 69:1995;149-173.
41. Schulze-Osthoff K., Los M., Baeuerle P.A. Redox signalling by transcription factors NF-kB and AP-1 in lymphocytes. Biochem. Pharmacol. 50:1995;735-741.
42. Lander H.M. An essential role for free radicals and derIved species in signal transduction. FASEB J. 11:1997;118-124.
43. Arlen R.R., Wells P.G. Extracellular thiol-disulfide status reflecting chemical toxicity mediated via oxidative stress: Validation with paraquat and t-butylhydroperoxide, and implications for phenytoin and thalidomide teratogenicity. FASEB J. 4:1990;A608.
44. Hu Z., Wells P.G. In vitro and in vivo biotransformation and covalent binding of benzo[a]pyrene in rats with a genetic deficiency in bilirubin UDP-glucuronosyltransferase. J. Pharmacol. Exp. Ther. 263:1992;334-342.
45. Vienneau D.S., DeBoni U., G Wells P. Potential genoprotective role for UDP-glucuronosyltransferases (UGTs) in chemical carcinogenesis: Initiation of micronuclei by benzo[a]pyrene and benzo[e]pyrene in UGT-deficient cultured rat skin fibroblasts. Cancer Res. 55:1995;1045-1051.
46. Hu Z., Wells P.G. Modulation of benzo[a]pyrene bioactivation and cytotoxicity by glucuronidation in lymphocytes and hepatic microsomes from rats with a hereditary deficiency in bilirubin UDP-glucuronosyltransferase. Toxicol. Appl. Pharmacol. 127:1994;306-313.
47. Z. Hu and P.G. Wells, Human interindividual variation in lymphocyte UDP-glucuronosyltransferases as a determinant of benzo(a)pyrene covalent binding and cytotoxicity. Proc. Int. Soc. for the Study of Xenobiotics (ISSX), vol. 4, 1993, p. 31.
48. Miranda A.F., Wiley M.J., Wells P.G. Evidence for embryonic peroxidase-catalyzed bioactivation and glutathione-dependent cytoprotection in phenytoin teratogenicity: Modulation by eicosatetraynoic acid and buthione sulfoximine in murine embryo culture. Toxicol. Appl. Pharmacol. 124:1994;230-241.
49. Allan J.M., Garner R.C. The use of purified DNA repair proteins to detect DNA damage. Mutation Res. 313:1994;165-174.
50. Sancar A. Mechanisms of DNA excision repair. Science. 266:1994;1954-1956.
51. P.E. Mirkes, Cellular responses to stress, in: R.J. Kavlock, G.P. Daston (Eds.), Handbook of Experimental Pharmacology, vol. 124, Part 1: Drug Toxicity in Embryonic Development, Springer-Verlag, Berlin, 1997, pp. 245-275.
52. Renzing J., Hansen S., Lane D.P. Oxidative stress is involved in the UV activation of p53. J. Cell Sci. 109:1996;1105-1112.
53. Norimura T., Nomoto S., Katsuki M., Gondo Y., Kondo S. p53 dependent apoptosis supresses radiation induced teratogenesis. Nature Med. 2:1996;577-580.
54. Hall P.A., Lane D.P. Tumor suppressors: A developing role for p53. Curr. Biol. 7:1997;144-147.
55. Wubah J.A., Ibrahim M.M., Gao X., Nguyen D., Pisano M.M., Knudsen T.B. Teratogen-induced eye defects mediated by p53-dependent apoptosis. Curr. Biol. 6:1996;60-69.
56. T.B. Knudsen, Cell death, in: R.J. Kavlock, G.P. Daston (Eds.), Handbook of Experimental Pharmacology, vol. 124, Part 1: Drug Toxicity in Embryonic Development, Springer-Verlag, Berlin, 1997, pp. 211-244.
57. Laposa R.R., Wiley M.J., Wells P.G. Evidence for non-apoptotic pathways mediating phenytoin teratogenicity in mice. Fundam. Appl. Toxicol. 36(Suppl. No. 1, Part 2):1997;98.